Abstract
This review displays the AGO Ovarian Cancer Study Group approach towards evaluation of improvement options in first-line therapy of advanced ovarian cancer. Prospectively randomized phase III trials evaluating the addition of newer drugs to standards carboplatin-paclitaxol (TC) as well as pilot trials evaluating new treatment modalities like anti-idiotype CA 125 antibodies or epidermal growth factor receptor (EGFR) modulation are presented.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Clinical Trials, Phase III as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Epirubicin / administration & dosage
-
Female
-
Gemcitabine
-
Humans
-
Neoplasm Metastasis
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Paclitaxel / administration & dosage
-
Research Design
-
Topotecan / administration & dosage
Substances
-
Deoxycytidine
-
Epirubicin
-
Topotecan
-
Carboplatin
-
Paclitaxel
-
Gemcitabine